TEAMS

Fiona Yu CEO

Before founding UnogenBio，Ms. Fiona Yu has over 20 years of corporate executive experience. She focuses on pharmaceutical strategy research and has accumulated extensive experience in the biopharmaceutical field in both China and the United States. Ms. Yu has written a series of strategic analysis articles about multinational pharmaceutical giants, which are generally considered to be of great reference and thinking value by senior people in the industry.

Mark Anderson CIO

Dr. Anderson leads Unogen’s science strategy and its execution with our biopharma collaboration partners. He is an oncology R&D leader with over 25 years of experience in the biotechnology and pharmaceutical industry, successfully initiating projects, developing agents utilizing novel and complex platforms, leading discovery and cross-functional compound development teams, and setting overall discovery and development strategy. He led teams that have taken multiple antibody based anti-cancer therapeutics to the NME stage, with several progressing to IND and clinical evaluation.

Oliver Kong CMO

President of Qilu Pharmaceutical Company, oversaw the clinical research and development of Qilu's clinical innovative drugs and biosimilar drugs. Before he joined Qilu, he was Vice President of Clinical Oncology of Hengrui USA. He previously served as the Global Medical Unit Head for Breast Cancer at Novartis Oncology. He also served as Senior Medical Director of Celgene Corporation and US Medical Director of Bayer Pharmaceuticals. He has over 28 years of experience in the pharmaceutical industry in clinical development and medical fields in various disease or therapeutic areas prior to oncology, autoimmune and infectious diseases.

Peter Cheung CSO

Prior to joining UnogenBio, Dr. Cheung has more than 25 years’ leadership role experience in biologics drug development, from the discovery research to proof-of-concept clinical stage. He served as senior executive position in multiple big pharma and biotech companies such as Johnson & Johnson, Adagene, Compugen, Biomed Valley Discovery, and Xencor. Dr. Cheung has led the successful filing of many INDs and was a key participant in the US approval of multiple BLAs. He is a pharmacologist, and was a postdoctoral fellow at MD Anderson Cancer Research Center.

Ho Yin Lo, Ph.D. Senior Vice President of Medicinal Chemistry

Dr. Lo is an experienced drug discovery and development leader, with over 20 years of industry pharmaceuticals experience in the USA and overseas. Including more than 10 years with Boehringer Ingelheim in Connecticut, 2 years with KBP Biosciences in Jinan, China and was the founder of Synovel Laboratory in Connecticut. Prior to joining Unogen, he was the chief operating officer of QX Therapeutics Inc in Connecticut and during his tenure, he had successfully led to 2 FDA IND in the US. He is knowledgeable and liaises with the US FDA and the IND process. He has a track record on advancing drug candidates to clinical trials in the US.He has published more than 19 peer review papers and is the inventor of 25 patents. Dr. Lo obtained his Ph.D. degree in The Chinese University of Hong Kong and Post-doctorate Fellow at Ohio State University.
loading